CytRx Gets Multiple Orphan Drug Designations For Aldoxorubicin

(RTTNews) - CytRx Corp. (CYTR) Monday said the U.S. Food and Drug Administration or FDA has granted multiple orphan drug designations for its drug candidate, aldoxorubicin, in three indications, which include glioblastoma multiforme or GBM, small cell lung cancer and ovarian cancer. The designation will provide aldoxorubicin seven years of U.S. market exclusivity in the specified indications.

The orphan drug status is given to a drug intended to treat a rare disease or condition, which is generally a disease that affects fewer than 200,000 individuals in the country.

Further, CytRx said it will report top-line results from both Phase 2 GBM trial and Phase 2 Kaposi's sarcoma trial in the first half of 2015.